Clinical sensitivity of cystic fibrosis mutation panels in a diverse population

The New York State Cystic Fibrosis Newborn Screening Consortium

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Infants are screened for cystic fibrosis (CF) in New York State (NYS) using an IRT-DNA algorithm. The purpose of this study was to validate and assess clinical validity of the US FDA-cleared Illumina MiSeqDx CF 139-Variant Assay (139-VA) in the diverse NYS CF population. The study included 439 infants with CF identified via newborn screening (NBS) from 2002 to 2012. All had been screened using the Abbott Molecular CF Genotyping Assay or the Hologic InPlex CF Molecular Test. All with CF and zero or one mutation were tested using the 139-VA. DNA extracted from dried blood spots was reliably and accurately genotyped using the 139-VA. Sixty-three additional mutations were identified. Clinical sensitivity of three panels ranged from 76.2% (23 mutations recommended for screening by ACMG/ACOG) to 79.7% (current NYS 39-mutation InPlex panel), up to 86.0% for the 139-VA. For all, sensitivity was highest in Whites and lowest in the Black population. Although the sample size was small, there was a nearly 20% increase in sensitivity for the Black CF population using the 139- VA (68.2%) over the ACMG/ACOG and InPlex panels (both 50.0%). Overall, the 139-VA is more sensitive than other commercially available panels, and could be considered for NBS, clinical, or research laboratories conducting CF screening.

Original languageEnglish (US)
Pages (from-to)201-208
Number of pages8
JournalHuman mutation
Issue number2
StatePublished - Feb 2016


  • CFTR
  • Clinical sensitivity
  • Cystic fibrosis
  • Mutation panel
  • NGS
  • Newborn screening
  • Next-generation sequencing

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)


Dive into the research topics of 'Clinical sensitivity of cystic fibrosis mutation panels in a diverse population'. Together they form a unique fingerprint.

Cite this